418 results on '"Cheng, Gregory"'
Search Results
2. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
3. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study
4. Effect of COVID-19 on patients with compensated chronic liver diseases
5. Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation
6. Pioneers of Magnetic Resonance
7. Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
8. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial
9. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study
10. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
11. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
12. Prednisolone Therapy Accelerated Recovery of Severe Drug-Induced Liver Injury: A Prospective Randomized Controlled Study
13. Haematological Manifestations In Patients With Severe Acute Respiratory Syndrome: Retrospective Analysis
14. Letter to the Editor: Obesity, diabetes, non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease are proinflammatory hypercoagulable states associated with severe disease and thrombosis in Covid-19
15. Antitumor activity of diethynylfluorene derivatives of gold(I)
16. Phyllanthus urinaria extract attenuates acetaminophen induced hepatotoxicity: Involvement of cytochrome P450 CYP2E1
17. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
18. Preparation of Galipea officinalis Hancock type tetrahydroquinoline alkaloid analogues as anti-tumour agents
19. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients
20. Synthesis and anti-cancer activity of benzothiazole containing phthalimide on human carcinoma cell lines
21. In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma
22. Reply to: “NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression – The debate continues”
23. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura
24. Factors Affecting the Maintenance Stable Warfarin Dosage in Hong Kong Chinese Patients
25. Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients
26. Achieving WHO target of HCV control in Hong Kong: challenges and strategies
27. Use of Herbal Medicines by Patients Receiving Warfarin
28. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone
29. Improve Warfarin Therapy or Use Dabigatran for Patients with Atrial Fibrillation - A Cost-Effectiveness Analysis: 1120465
30. Eltrombopag for the treatment of immune thrombocytopenia
31. Reply to Yoshioka et al
32. Enhanced Protein Damage Clearance Induces Broad Drug Resistance in Multitype of Cancers Revealed by an Evolution Drug‐Resistant Model and Genome‐Wide siRNA Screening
33. Reply to Grifoni et al
34. Reply to: ‘No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease’
35. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study
36. Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score
37. Safety and efficacy of eltrombopag plus pulsed dexamethasone as first‐line therapy for immune thrombocytopenia
38. Clinical Characteristics Predicting Progression of COVID-19
39. Simultaneous measurement of S-warfarin, R-warfarin, S-7-hydroxywarfarin and R-7-hydroxywarfarin in human plasma by liquid chromatography–tandem mass spectrometry
40. Hematology and Immunology
41. Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy
42. JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia
43. Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with oral danazol and steroid
44. Management of Chinese patients on warfarin therapy in two models of anticoagulation service – a prospective randomized trial
45. Use of Cefoperazone Still Needs a Caution for Bleeding From Induced Vitamin K Deficiency
46. A mathematical model for fresh frozen plasma transfusion strategies during major trauma resuscitation with ongoing hemorrhage
47. ABO Blood Group and Susceptibility to Severe Acute Respiratory Syndrome
48. The Effects of Nasal Continuous Positive Airway Pressure on Platelet Activation in Obstructive Sleep Apnea Syndrome*
49. High-Dose Dexamethasone as Initial Treatment for Immune Thrombocytopenic Purpura
50. Outcomes of long-term warfarin therapy under two ambulatory care models in Hong Kong
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.